Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C

ABSTRACT

Introduction: We used published literature from 2013–2016, to review data regarding the new all oral interferon and ribavirin free direct acting antiviral (DAA’s) treatment regimens.

Areas covered: Specifically, this paper will address DAA’s clinical efficacy, their associated patient reported outcomes, their adherence to treatment, and their cost-effectiveness of treatment using studies from the United States.

Expert commentary: The current data suggest that cure and elimination of HCV appears to be on the horizon; however, more research is needed to verify similar results from real world practices. Further, research is also needed to overcome the barriers to treatment (lack of education and awareness of HCV, inadequate diagnosis technology, and lack of access and link to care) in order for the elimination of HCV to be obtained.

KEYWORDS:

• Patient reported outcomes
• ethics
• cost-effectiveness
• adherence
• access to care
• barriers

Declaration of interest

Z Younossi is a consultant for Gilead Science. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Additional information

Funding

This manuscript did not receive any funding.